# Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors

> **NCT01331135** · PHASE1 · COMPLETED · sponsor: **Emory University** · enrollment: 18 (actual)

## Conditions studied

- Ewing's Sarcoma
- Osteosarcoma
- Astrocytoma
- Atypical Teratoid/Rhabdoid Tumor
- Ependymoma
- Germ Cell Tumor
- Glioma
- Medulloblastoma
- Rhabdoid Tumor
- Retinoblastoma
- Clear Cell Sarcoma
- Renal Cell Carcinoma
- Wilms Tumor
- Hepatoblastoma
- Neuroblastoma
- Rhabdomyosarcoma

## Interventions

- **DRUG:** sirolimus

## Key facts

- **NCT ID:** NCT01331135
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2017-08-09
- **Final completion:** 2017-08-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01331135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01331135, "Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01331135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*